Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06697197
Recruiting Phase 1/2

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

NCT06697197 · tracked via the Priya Life Science Italy tracker
Sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Started
2025-02-17
Last updated
2026-02-03

Condition(s) studied

Advanced Solid Tumors

Investigational drug(s) / intervention(s)

BMS-986482Nivolumab and rHuPH20 →Nivolumab/relatlimab/rHuPH20 →Bevacizumab →

BMS-986482: Specified dose on specified days

Nivolumab and rHuPH20: Specified dose on specified days

Nivolumab/relatlimab/rHuPH20: Specified dose on specified days

Bevacizumab: Specified dose on specified days

Study summary

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant. * Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF. Exclusion Criteria: * History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures. * Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator. * Other protocol-defined Inclusion/Exclusion criteria apply.

Primary outcome measure(s)

  • Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0) — Up to 135 days post last treatment visit
  • Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0 — Up to 135 days post last treatment visit
  • Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0 — Up to Day 28
  • Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0 — Up to 135 days post last treatment visit
  • Number of deaths as assessed by NCI-CTCAE v5.0 — Through study completion (Up to 4 years)

Trial sites (21)

FacilityCityRegionStatus
University of California, Irvine (UCI) Health - UC Irvine Medical Center Irvine California Recruiting
The Angeles Clinic and Research Institute - West Los Angeles Office Los Angeles California Recruiting
Local Institution - 0008 Aurora Colorado Not Yet Recruiting
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey Recruiting
Northwell Health/ RJ Zuckerberg Cancer Center Lake Success New York Recruiting
Levine Cancer Institute Charlotte North Carolina Recruiting
Fred Hutchinson Cancer Center Seattle Washington Recruiting
UZ Gent Ghent Oost-Vlaanderen Recruiting
Rigshospitalet Copenhagen Capital Region Recruiting
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone Marseille Bouches-du-Rhône Recruiting
Gustave Roussy Villejuif Paris Recruiting
General Hospital of Athens "Laiko" Athens Attikí Recruiting
Papageorgiou General Hospital of Thessaloniki Thessaloniki Thessaloníki Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori Milan Lombardy Recruiting
Istituto Clinico Humanitas Rozzano Milano Recruiting
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) Amsterdam North Holland Recruiting
Erasmus Medisch Centrum Rotterdam Netherlands Recruiting
Hospital Universitari Vall d'Hebron Barcelona Barcelona [Barcelona] Recruiting
Clinica Universidad de Navarra Pamplona Navarre Recruiting
Hospital Universitario HM Sanchinarro Madrid Spain Recruiting
Karolinska Universitetssjukhuset Solna Solna Stockholms Län [se-01] Recruiting

On this site

📄 Avastin (bevacizumab) drug profile →

More Bristol-Myers Squibb trials in Italy

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy Recruiting
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Recruiting
A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease Recruiting
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02) Starting soon
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis Recruiting

Other trials for the same condition

A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation Recruiting
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors Active, not recruiting
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors Active, not recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) Recruiting
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06697197 on ClinicalTrials.gov ↗ ← All trials in Italy